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The NEAT trial reported considerable benefit for ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil)
of 28% for relapse-free survival (RFS) and 30% for overall survival (OS), when compared with classical CMF in early breast cancer. To
assess tolerability, toxicity, dose intensity and quality of life (QoL) analyses were undertaken. All 2021 eligible patients had common
toxicity criteria (CTC), delivered chemotherapy and supportive treatments details and long-term morbidities recorded. The QoL
substudy used multiple validated measures. ECMF produced low CTC scores, although higher than CMF for nausea, vomiting,
alopecia, constipation, stomatitis (Po0.001), infection (P¼0.001) and fatigue (P¼0.03). Supportive treatments required, however,
were similar across randomised treatments. On-treatment deaths were more common with CMF (13) than ECMF(5). Optimal
course-delivered dose intensity (CDDI X85%) was received more often by ECMF patients (83 vs 76%: P¼0.0002), and was
associated with better RFS (P¼0.0006). QoL over 2 years was equivalent across treatments, despite minimally worse side effects for
ECMF during treatment. ECMF benefit spanned all levels of toxicity, CDDI and QoL. There are no reported acute myeloid
leukaemias or cardiac dysfunctions. ECMF is tolerable, deliverable, and significantly more effective than CMF, with no serious long-
term toxicity or QoL detriment.
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The National Epirubicin Adjuvant Trial (NEAT) started in 1996,
when recorded benefits of adjuvant breast cancer chemotherapy
were small, in terms of absolute percentage of advantages in
relapse-free survival (RFS) and overall survival (OS) (Peto, 1992,
1998). Attention was therefore also focused on the ‘cost’ of such
treatment in terms of toxicity and quality of life (QoL) (Aaronson
et al, 1993; Sprangers et al, 1996). The primary end point of
NEAT was to establish whether the anthracycline-based regimen
ECMF (epirubicin, cyclophosphamide, methotrexate, 5-fluorouracil)
(Bonadonna et al, 1995a) would be an improvement on standard
classical CMF. With a median follow-up of 4 years, NEAT showed a
highly significant 28% advantage in RFS and 30% advantage in OS,
with these advantages increasing to 31 and 33%, respectively, when
analysed in a meta-analysis with the BR9601 trial (Poole et al, 2006).
The secondary end points of NEAT were to compare ECMF and
CMF in terms of toxicity and QoL. These results are reported here.
In addition, we investigated whether ECMF was deliverable with the
dose intensity required to achieve the hypothesised improvements
in activity over CMF. Hryniuk and Bush (1984) had already analysed
the importance of dose intensity in terms of effectiveness.
PATIENTS AND METHODS
NEAT was a large, randomised, phase III trial comparing optimally
scheduled anthracyclines (ECMF) with CMF in women with
early-stage breast cancer. The two randomised treatments were:
epirubicin (100mgm
 2 every 3 weeks) 4 cycles followed by CMF
(cyclophosphamide 100mgm
 2 po days 1–14 or cyclophospha-
mide 600mgm
 2 day 1 and 8, i.v.; methotrexate 40mgm
 2 days 1
and 8; 5-fluorouracil 600mgm
 2 days 1 and 8 every 4 weeks) 4
cycles (ECMF) vs CMF 6 cycles.
Toxicity, dose intensity and supportive treatment
For each cycle, data were collected on chemotherapy doses and
dates, and common toxicity criteria (CTC) gradings for 10
common toxicities. Hospital admissions and details of supportive
treatment were recorded including use of antiemetics, prophylactic
antibiotics, growth factors and blood transfusions.
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sDeaths during/attributed to chemotherapy and second
malignancies
Deaths were recorded on annual follow-up forms. In the absence
of disease progression, all deaths during chemotherapy were
attributed to chemotherapy although all causes of death were also
recorded. Details of second malignancies, including myelodys-
plasia, experienced during the follow-up period were recorded.
Quality of life
The QoL substudy was offered to all patients until the accrual
target of 500 was met. QoL booklets comprised the EORTC QLQ-
C30 (Aaronson et al, 1993), the EORTC QLQ-BR23 (Sprangers
et al, 1996) and a Women’s Health Questionnaire (WHQ) (Hunter,
1992). Booklets were completed by participating patients at
baseline, mid-chemotherapy, end of chemotherapy and 12 months
and 24 months after baseline.
The NEAT trial was approved by a multicentre research ethics
committee and by the local research ethics committee at each
participating hospital.
STATISTICAL METHODS
Toxicity
Worst toxicity grades For each of the 10 listed toxicities, patient’s
worst severity during chemotherapy was identified and these
compared across treatments using w
2 tests for trend. Sensitivity
analysis was undertaken using data only from patients with full
toxicity information on all their received cycles.
Incidence of severe toxicity The number of cycles where each of
the 10 listed toxicities was suffered at a severe level (CTC grade 3
or above (two for alopecia)) was compared across treatments
using w
2 tests with continuity corrections. Frequency of supportive
treatment use, a substitute measure of toxicity, was summarised.
The number of patients deemed to have suffered a severe toxicity
at any point throughout their entire treatment course was
determined using toxicity reporting and reasons for treatment
delay, reduction or hospitalisation. These frequencies were
then compared across treatments using w
2 tests with continuity
corrections.
Chemotherapy
Course delivered dose intensity (CDDI) was calculated as follows:
(i) a per drug dose intensity (administered dose per day divided by
the planned mgm
 2day
 1); (ii) a per cycle dose intensity
(averaging all drug dose intensities planned for that cycle); and
(iii) a per patient CDDI was calculated (averaging the above over
all planned cycles). Patients with calculable CDDI were compared
across treatments using Wilcoxon rank sum tests. The influence of
prognostic factors was analysed by multiple regression and logistic
regression.
Quality of life
The C30 questionnaire consists of three scales (15 subscales, 30
questions), the BR23 questionnaire 2 scales (eight subscales, 23
questions) and the WHQ 1 scale (nine subscales, 37 questions).
Standardised area under the curve analysis (Qian et al, 2000) was
undertaken for QoL scales and subscales during the on-treatment
period and treatments compared by each scale using O’Brien’s
global rank procedure (O’Brien, 1984). If significance was found,
subscales were investigated with Wilcoxon rank sum tests. To
assess long-term QoL, changes from baseline to 1 year and baseline
to 2 years were assessed across treatments using O’Brien’s global
rank procedure and Wilcoxon rank sum tests.
Prediction of RFS
Kaplan–Meier (Kaplan and Meier, 1958) survival curves were
constructed and the log-rank test (Peto et al, 1977) was used to
assess any differences between CDDI levels. Toxicity, dose
intensity and QoL effects on the ECMF benefit over CMF in
respect of risk of relapse or death were assessed using forest plots
(Early Breast Cancer Trialists’ Collaborative Group, 1990).
RESULTS
Patient characteristics of the 2021 eligible patients, recruited by
111 consultants from 65 UK centres, were balanced across
randomised treatments (Supplementary Table 1).
Toxicity
Toxicity information is available from 12442 cycles (91% of those
with treatment information), from 1952 (97%) patients; 7144
(92%) cycles from 979 ECMF patients and 5298 (91%) cycles from
973 CMF patients. Generally, patients reported low levels of
toxicity, although ECMF patients suffered significantly more
nausea, vomiting, stomatitis, alopecia, constipation, infection,
and fatigue (Tables 1 and 2). The excesses in infections and fatigue,
however, were only of a mild nature. The 1543-patient subset with
Table 1 Worst severity suffered by patient, throughout all cycles for
each stated toxicity
ECMF (n¼979) CMF (n¼973)
Toxicity Grade N % N % P*
Nausea
a 0 134 13 244 25 o0.001
1/2 697 71 657 67
3 146 15 69 7
Vomiting 0 451 46 609 63 o0.001
1/2 412 42 327 33
3/4 113 11 36 3
Stomatitis 0 283 29 437 45 o0.001
1/2 634 64 507 52
3/4 61 6 27 3
Alopecia
a 0 87 9 234 24 o0.001
1 72 7 472 48
2 820 84 263 27
Constipation 0 516 53 674 69 o0.001
1/2 390 40 271 28
3/4 62 6 24 2
Infection 0 418 43 505 52 0.001
1/2 465 47 397 41
3/4 64 7 51 5
Fatigue
a 0 131 13 154 16 0.03
1/2 638 65 640 65
3 204 21 177 18
Neutropenia 0 652 67 676 69 40.99
1/2 162 16 140 14
3/4 151 15 143 15
Thrombocytopenia 0 916 93 907 93 40.99
1/2 54 6 55 6
3/4 8 1 10 1
Diarrhoea 0 541 55 512 53 40.99
1/2 380 39 401 41
3/4 56 6 58 6
*P-values after Bonferroni correction from tests on full breakdown of toxicity grades.
aCTC gradings for nausea and fatigue have a maximum of three and, for Alopecia, a
maximum of two.
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substantially different results.
Neutropenic sepsis Neutropenia was suffered at any grade in 1501
(12%) cycles and infection in 1914 (15%) cycles. Neutropenic
sepsis, defined as concurrent neutropenia and infection was
reported in 346 (3%) cycles (3% ECMF; 3% CMF, P¼0.84), by
247 (13%) patients (14% ECMF; 11% CMF, P¼0.06).
Supportive treatment Supportive treatment information is avail-
able for all 13625 cycles that have been completed by 2012 eligible
patients (7777 ECMF, 5848 CMF). Antiemetics were administered
in 97% of cycles (98% of cycles by ECMF patients, 97% of cycles by
CMF patients) (Supplementary Table 2). The antiemetics used
were non-5HT3’s (82%), dexamethasone (75%), and 5HT3’s (69%).
In 12% of cycles, antibiotics were administered (13% during ECMF
patients’ cycles, 9% during CMF patients’ cycles). More anti-
bacterials than antifungals were given (70 vs 50% respectively).
Only 77 cycles (0.5% of the 13625) were supplemented by growth
factor support, balanced across treatments. Hospitalisation was
reported in only 4% of cycles, balanced across treatments, the
main reason being sepsis (41%). Blood and platelet transfusions
were low in incidence (0.6 and 0.04% of cycles respectively).
Chemotherapy
Number of cycles Full treatment information was reported for
1985 (98%) patients: 987 (98%) ECMF and 998 (99%) CMF. All
planned cycles were received by 891 (90%) ECMF patients and 929
(93%) CMF patients (P¼0.03). Thirty-two (2%) patients received
p2 cycles of chemotherapy; 3 of these receiving no treatment at
all. Reasons for not completing the full course were toxicities or
unspecified personal reasons.
Drug doses received Oral cyclophosphamide had the lowest
overall percentage of dose received (88%) (Table 3), expected
when comparing with i.v. drugs, which can be administered with
precision to within 1mg, whereas oral administration is limited
because of the fixed tablet size (50mg). Epirubicin has the highest
overall percentage of dose received, perhaps because it is given as
the first 4 cycles and therefore less likely to be affected by
reductions because of cumulative toxicities.
Treatment delays The median cycle duration was as stated in the
protocol: the first 4 cycles on the ECMF arm had median 21 days
duration (range 16–84); the last 4 cycles, 28 days (range 20–91);
and cycles on the CMF arm had a median 28-day duration (range
17–101). However, CMF patients appear to have suffered margin-
ally more delays despite receiving two fewer cycles (Table 4).
Overall, 2376 (18%) cycles were delayed; 1294 (17%) ECMF
and 1082 (19%) CMF (P¼0.008). The median delay was 1 week
for both treatments (range 2 days–10 weeks), caused mainly
by haematological problems, although longer delays were usually
because of patients receiving concurrent radiotherapy. Only 358
(35%) ECMF and 436 (43%) CMF patients suffered no delays.
Dose reductions Overall, 865 (6%) cycles were dose reduced: 400
(5%) cycles by ECMF patients and 465 (8%) by CMF patients
(Po0.001). The main reason for dose reduction was haematolo-
gical toxicity. Eight hundred and twelve (80%) ECMF patients and
807 (80%) CMF patients suffered no reductions.
Delivered dose intensity Oral cyclophosphamide had the lowest
drug dose intensity, with epirubicin and i.v. cyclophosphamide
having the highest (Table 3) intensity. There was no apparent
decrease of cycle-delivered dose intensity as treatment progressed
(Supplementary Figure 1). Median CDDI received was 94% (IQR
87–101%): 94% (range 89–101%) for ECMF and 92% (range
85–100%) for CMF (Po0.0001). Eighty percent of patients
achieved the X85% CDDI; 83% ECMF patients and 76% CMF
patients (P¼0.0002). Analysis of RFS by patients who received
o85% CDDI or X85% CDDI, demonstrates a significant
difference in favour of X85% CDDI (P¼0.0006). This difference
is present in both randomised treatment arms (Figure 1).
Table 3 Drug doses received and drug delivered dose intensity (dDDI)
ECMF CMF
Drugs % dose received Median (IQR) dose intensity % dose received Median (IQR) dose intensity
Epirubicin 99 100 (95–105) 100
a 99 (99–100)
Oral Cyclophosphamide 89 88 (78–105) 88 87 (77–104)
i.v. Cyclophosphamide 96 100 (93–104) 96 100 (92–104)
Methotrexate 97 99 (92–104) 97 99 (91–104)
5-FU 97 99 (93–104) 97 99 (91–104)
aBased on two CMF patients who received Epirubicin through protocol violations.
Table 2 Incidences of severe
a toxicity suffered by cycle and by patient
ECMF CMF Total
N % N % N %
Number of cycles (n¼7144) (n¼5298) (n¼12442)
Nausea 204 2.9 89 1.7 293 2
Vomiting 172 2.4 45 0.9 217 2
Stomatitis 86 1.2 34 0.6 120 1
Alopecia 3850 53.9 769 14.5 4619 37
Constipation 100 1.4 37 0.7 137 1
Infection 76 1.1 62 1.2 138 1
Fatigue 429 6.0 326 6.2 755 6
Neutropenia 275 3.9 227 4.3 502 4
Thrombocytopenia 10 0.1 11 0.2 21 1
Diarrhoea 78 1.1 87 1.6 165 1
Neutropenic Sepsis
b 201 3 145 3 346 3
Number of patients
c (n¼1004) (n¼1008) (n¼2012)
Nausea 169*** 17 85 8 254 13
Vomiting 129*** 13 48 5 177 9
Stomatitis 70** 7 33 3 103 5
Alopecia 821*** 82 263 26 1084 54
Constipation 63*** 6 26 3 89 4
Infection 208 21 163 16 371 18
Fatigue 212 21 183 18 395 20
Neutropenia 334 33 347 34 681 34
Thrombocytopenia 26 3 21 2 47 2
Diarrhoea 72 7 77 8 149 7
Asterisks indicate significantly higher number of patients, after Bonferroni correction
(*Po0.05, **Po0.01, ***Po0.001).
aSevere¼reported CTC grade X3( X2 for
alopecia).
bNeutropenic Sepsis episodes inferred from incidences, of any grade, of
neutropenia and infection reported in the same cycle.
cGleaned from a reported
severe grade or cause of treatment delay, reduction or hospitalisation.
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sQuality of life
The QoL substudy achieved its target sample with 511 patients
(25%) (27% ECMF, 23% CMF), which was comparable with the
main trial set in terms of patient characteristics, CDDI, RFS and
OS. QoL form return was excellent, and balanced across treatments
(P¼0.57). All 511 patients completed baseline forms, 453 (89%)
mid-chemotherapy forms, 449 (88%) end-of-treatment forms, 436
(85%) 1-year forms and 411 (80%) 2-year forms. The rate of
missing individual question responses was low (4%) and balanced
across treatments (4% ECMF, 3.5% CMF). In total, 1595 (71%)
questionnaire packs had fewer than five missing responses to the
90 questions. Forty four percent of all missing responses were to
sexual questions in the QLQ-BR23 and WHQ. The timing of the
Table 4 Treatment delays and dose reductions per treatment cycle
a on 13454 cycles
ECMF (n¼7658) CMF (n¼5796) Total (n¼13454)
N % N % N %
Delays suffered within cycle 1294 17 1082 19 2376 18
Length of delay (days)
Median (IQR) 7 (5–7) 7 (7–7) 7 (6–7)
Range 2–63 2–73 2–73
Reasons for delay
Haematological 400 31 446 41 846 36
Admin/personal reasons 130 10 98 9 228 10
Radiotherapy 85 7 69 6 154 6
Other 156 12 112 10 268 11
Unknown 529 41 371 34 900 38
Dose reduction within cycle 400 5 465 8 865 6
Reasons for dose reduction
Haematological 119 30 124 27 243 28
Admin/personal reasons 12 3 20 4 32 4
Other 94 23 95 20 189 22
Unknown 175 44 228 49 403 46
aDelay defined as 41 day late from previous cycle; Reduction defined as o85% of expected doses. Some cycles were delayed or reduced for more than one reason.
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P=0.0006
Years after surgery
Years after surgery
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01234 5
Years after surgery
012345
Figure 1 Relapse-free survival by CDDI (o85%, X85%).
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treatments, except for slightly later end-of-treatment QoL forms
for CMF patients (median 19 days late vs 13 days late for ECMF
patients, P¼0.04).
Five hundred and one patients had both a completed baseline
and mid and/or end-of-treatment questionnaire. The BR23
questionnaire detected a higher frequency of symptoms for ECMF
patients during treatment (P¼0.05). The subscales identified
increased ‘Systemic therapy side effects’ and ‘Upset by hair loss’
(P¼0.0001 and o0.0001 respectively). No other scales highlighted
differences during treatment (C30 Function P¼0.13, Global Health
P¼0.44 and Symptom P¼0.50; BR23 Function P¼0.16, WHQ
Global P¼0.13). The baseline to 1-year change analysis detected
differences in both the C30 Global Health and C30 Symptom scale
in favour of the ECMF patients (P¼0.01 and 0.04 respectively).
The subscales indicated ECMF patients had greater improvements
in global QoL from baseline compared with fewer improvements
experienced by CMF patients (P¼0.01, Figure 2). In addition,
CMF patients appeared to be suffering more treatment-related
symptoms at 1 year compared with baseline, as opposed to ECMF
patients who had similar baseline and 1-year symptom scores.
Treatment differences disappeared by 2 years.
Deaths during/attributed to chemotherapy
Out of the 2021 patients randomised, 18 suffered deaths attributed
to chemotherapy (o1%; 5 ECMF: 13 CMF). The most common
cause of death was neutropenic sepsis (eight patients) with five
fatal pulmonary emboli, and four cerebrovascular accidents. In one
patient the cause of death could not be established despite autopsy,
and the patient died with a normal blood count. All deaths on
treatment in ECMF patients occurred during the CMF phase of the
treatment.
Age and performance status in the prediction of CDDI and
toxicity
Age demonstrated no prognostic value for CDDI (P¼0.62),
although performance status (PS) showed a slight trend towards
PS 2 patients achieving a lower median CDDI (85% (IQR¼65–94)
(P¼0.07)). Age had no effect on CDDI categorised as o85 or
X85% (P¼0.65), but PS had a significant prognostic value. PS 0
had 80% patients with CDDI X85%, PS 1 had 77% patients and PS
2 had 50% (P¼0.05). Predicting severe toxicity suffered during
treatment demonstrated that age 450 years and PS 2 predicted for
a higher incidence of severe neutropenia (P¼0.003 and Po0.0001
respectively).
CDDI, toxicity and QoL in the prediction of RFS
Analysis of the interaction between toxicity, CDDI, and QoL with
the RFS benefits observed for all ECMF patients, show no
statistically significant heterogeneity or trends. The benefit of
ECMF over CMF holds true for all patients in the study, over the
full range of experiences of toxicities, CDDI and QoL.
Second malignancies and cardiac morbidity
Forty-seven patients have reported second malignancies (2%).
Over half of these are second primaries in the contralateral breast
(Supplementary Table 3). Only one patient has been reported with
acute leukaemia, which was pro-myelocytic in type, and judged
unrelated to chemotherapy. There are no reports of cardiac
morbidity.
DISCUSSION
The results of the NEAT study have been published in detail
elsewhere (Poole et al, 2006) but in summary, show considerable
advantages in terms of RFS (28%) and OS (30%) for patients
receiving ECMF compared with CMF. ECMF demonstrated low
rates of toxicity, although more than were recorded in CMF
patients. Interestingly, more deaths during treatment occurred on
the CMF arm and deaths that occurred on the ECMF arm were all
during CMF, although we were unable to identify any early
warning indicators for treatment-related deaths. A continued high
level of vigilance is required in all patients receiving adjuvant
chemotherapy for breast cancer.
Bonadonna et al (1995b) reported total dose delivered in the
retrospective analysis of their original CMF vs control adjuvant
breast cancer trial and demonstrated that when total doses were
below 85% there was no advantage compared with the ‘no
treatment’ control arm. Hryniuk’s work on delivered dose intensity
added increased sophistication to this important emerging concept
(Hryniuk and Bush, 1984). The median CDDI was high in NEAT at
94%, and optimal CDDI (X85%) was more often achieved in
ECMF than CMF patients (83 vs 76% respectively; P¼0.0002). In
addition, significantly higher RFS was shown for optimal (X85%)
CDDI compared with reduced CDDI (P¼0.0006), and this held for
both the ECMF and CMF arms. These data confirm the
deliverability
of ECMF.
It is often said that older patients and those with low
performance status suffer more toxicity from chemotherapy, and
therefore dose intensity may be compromised. Although this is
undoubtedly true for the 65 years plus age group, in this study we
were able to analyse whether being under or over the age of 50
years made any difference to toxicity, CDDI, or QoL. Multiple
regression analysis was carried out to look for prediction by age
and performance status (PS) of CDDI. It was only PS 2 patients
who showed a slight trend towards achieving a lower median CDDI
(85% (IQR¼65–94) (P¼0.07)). Logistic regression confirmed
this showing that only 50% of PS 2 patients achieved an optimal
CDDI X85% (P¼0.05). Age 450 years and PS 2 predicted for a
higher incidence of neutropenia (P¼0.003 and Po0.0001
respectively) only, out of all possible toxicities.
Analysis of interaction between toxicity, CDDI, and QoL with
treatment effect (ECMF vs CMF) with tests for heterogeneity and
trends, show no statistically significant effects. This is important as
it shows that the benefit of ECMF over CMF holds true for all
patients in the study, over the full range of experiences of different
toxicities, CDDI and QoL.
Quality-of-life assessment is an important part of the analysis of
results in cancer clinical trials. The collection of over 80% of
longitudinal data in more than 500 patients makes it possible for
us to draw some important conclusions. Although there was some
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Figure 2 Box and Whisker plots of EORTC QLQ-C30 global QoL
domain over time.
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patients in the ECMF arm, the improvements in RFS and OS far
outweighed this small and transitory reduction in QoL.
In conclusion, the tolerability and acceptability of the NEAT
treatment regimens were critical end points. Despite differences in
acute toxicities and short-term QoL between ECMF and CMF, both
regimens were shown to be tolerable, with the majority of patients
receiving X85% CDDI. Only low levels of supportive treatments
and hospitalisations were necessary, and both regimens were
associated with similar long-term QoL outcomes. The benefit for
ECMF over CMF holds true for all groups of patients regardless of
toxicity, CDDI or QoL.
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